Eikon Therapeutics (EIKN) FDA Approvals $10.98 -0.54 (-4.69%) As of 08/28/2026 04:00 PM Eastern Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsNews and TrendsOwnershipSEC FilingsShort Interest Eikon Therapeutics' Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Eikon Therapeutics (EIKN). Over the past two years, Eikon Therapeutics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as EIK1001. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. EIK1001 FDA Regulatory Timeline and Events EIK1001 is a drug developed by Eikon Therapeutics for the following indication: patients with stage IV NSCLC. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Dose Update - August 11,2026Dose Update Drug: EIK1001Announced Date: August 11, 2026Indication: patients with stage IV NSCLCAnnouncementEikon Therapeutics, Inc. announced the selection of a dose of 0.60 mg/m2 that will be employed in future for all patients randomized to receive EIK1001 in the TeLuRide-006 trial.Read AnnouncementDose Update - July 27,2026Dose Update Phase 2/3Drug: EIK1001Announced Date: July 27, 2026Indication: patients with stage IV NSCLCAnnouncementEikon Therapeutics, Inc. announced that the first patient has been dosed in TeLuRide-008, a Phase 2/3 registrational study evaluating EIK1001 in combination with pembrolizumab and histology-appropriate chemotherapy as first-line therapy for treatment-naïve patients with stage 4 Non-Small Cell Lung Cancer (NSCLC).AI SummaryEikon Therapeutics, Inc. announced that the first patient has been dosed in TeLuRide-008, a Phase 2/3 registrational clinical trial of EIK1001. The study is evaluating EIK1001 in combination with pembrolizumab and chemotherapy selected for the patient’s cancer type. It is designed for patients with newly diagnosed, stage 4 non-small cell lung cancer (NSCLC) who have not previously received treatment for advanced disease. The trial will assess whether this combination can provide a meaningful treatment option for people with advanced NSCLC. As a registrational study, its results could support future regulatory applications if the treatment is shown to be safe and effective. Eikon noted that statements about the trial and EIK1001’s potential are forward-looking and involve risks and uncertainties. The company said these statements reflect information available at the time of the announcement and may not be updated unless required by law.Read AnnouncementAbstract - July 20,2026Abstract Drug: EIK1001Announced Date: July 20, 2026Indication: patients with stage IV NSCLCAnnouncementEikon Therapeutics, Inc. announced the acceptance of seven abstracts covering progress across its lead programs at the 2026 European Society of Medical Oncology (ESMO) Congress in Madrid, Spain.AI SummaryEikon Therapeutics announced that seven abstracts from its clinical pipeline were accepted for presentation at the 2026 European Society of Medical Oncology (ESMO) Congress in Madrid. The updates cover several lead programs, including EIK1001, EIK1003, EIK1004, and EIK1005, across a range of cancers. For EIK1001, the company will share Phase 2 results in stage IV non-small cell lung cancer, including data from the squamous cohort, as well as a Phase 2/3 study combining the drug with pembrolizumab and chemotherapy. EIK1003 data will include studies in metastatic prostate cancer and advanced solid tumors. EIK1004 will be presented as a first-in-human study in patients with advanced solid tumors carrying HRR mutations. EIK1005 presentations will cover its use as a monotherapy and with pembrolizumab, along with safety, tolerability, and pharmacokinetic findings. The company said the abstracts reflect progress across its pipeline, but noted that forward-looking statements should not be relied on too heavily.Read Announcement Eikon Therapeutics FDA Events - Frequently Asked Questions Has Eikon Therapeutics received FDA approval? As of now, Eikon Therapeutics (EIKN) has not received any FDA approvals for its therapy in the last two years. What drugs has Eikon Therapeutics submitted to the FDA? In the past two years, Eikon Therapeutics (EIKN) has reported FDA regulatory activity for EIK1001. What is the most recent FDA event for Eikon Therapeutics? The most recent FDA-related event for Eikon Therapeutics occurred on August 11, 2026, involving EIK1001. The update was categorized as "Dose Update," with the company reporting: "Eikon Therapeutics, Inc. announced the selection of a dose of 0.60 mg/m2 that will be employed in future for all patients randomized to receive EIK1001 in the TeLuRide-006 trial." What conditions do Eikon Therapeutics' current drugs treat? Currently, Eikon Therapeutics has one therapy (EIK1001) targeting the following condition: patients with stage IV NSCLC. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Amarin FDA EventsCytokinetics FDA EventsQuoin Pharmaceuticals FDA EventsEli Lilly and Company FDA EventsAdicet Bio FDA EventsAmgen FDA EventsBioLineRx FDA EventsBioNTech FDA EventsCorvus Pharmaceuticals FDA EventsCytomX Therapeutics FDA EventsFibroBiologics FDA EventsGilead Sciences FDA EventsHUTCHMED FDA EventsMBX Biosciences FDA EventsModerna FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Precigen FDA Events Nuvation Bio FDA Events Vericel FDA Events Vera Therapeutics FDA Events Mesoblast FDA Events Agios Pharmaceuticals FDA Events Nanobiotix FDA Events Biohaven FDA Events Septerna FDA Events Zenas BioPharma FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:EIKN last updated on 8/11/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredWhy Boston Ships In Natural Gas It Already Has at HomeA tanker called the Iberica Knutsen once sailed 2,272 miles from Trinidad and Tobago to deliver liquefied natu...Porter & Company | SponsoredSPDR Gold just lost $14 billion.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...Behind the Markets | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredA Worldwide Gold Lockdown Is Now UnderwayGold has spiked above $4,400 an ounce as central bankers stockpile at one of the fastest paces in decades, acc...Stansberry Research | SponsoredWhy the Treasury still prices gold at 42 dollars an ounceThe U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades n...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eikon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eikon Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Dose Update - August 11,2026Dose Update Drug: EIK1001Announced Date: August 11, 2026Indication: patients with stage IV NSCLCAnnouncementEikon Therapeutics, Inc. announced the selection of a dose of 0.60 mg/m2 that will be employed in future for all patients randomized to receive EIK1001 in the TeLuRide-006 trial.Read Announcement
Dose Update - July 27,2026Dose Update Phase 2/3Drug: EIK1001Announced Date: July 27, 2026Indication: patients with stage IV NSCLCAnnouncementEikon Therapeutics, Inc. announced that the first patient has been dosed in TeLuRide-008, a Phase 2/3 registrational study evaluating EIK1001 in combination with pembrolizumab and histology-appropriate chemotherapy as first-line therapy for treatment-naïve patients with stage 4 Non-Small Cell Lung Cancer (NSCLC).AI SummaryEikon Therapeutics, Inc. announced that the first patient has been dosed in TeLuRide-008, a Phase 2/3 registrational clinical trial of EIK1001. The study is evaluating EIK1001 in combination with pembrolizumab and chemotherapy selected for the patient’s cancer type. It is designed for patients with newly diagnosed, stage 4 non-small cell lung cancer (NSCLC) who have not previously received treatment for advanced disease. The trial will assess whether this combination can provide a meaningful treatment option for people with advanced NSCLC. As a registrational study, its results could support future regulatory applications if the treatment is shown to be safe and effective. Eikon noted that statements about the trial and EIK1001’s potential are forward-looking and involve risks and uncertainties. The company said these statements reflect information available at the time of the announcement and may not be updated unless required by law.Read Announcement
Abstract - July 20,2026Abstract Drug: EIK1001Announced Date: July 20, 2026Indication: patients with stage IV NSCLCAnnouncementEikon Therapeutics, Inc. announced the acceptance of seven abstracts covering progress across its lead programs at the 2026 European Society of Medical Oncology (ESMO) Congress in Madrid, Spain.AI SummaryEikon Therapeutics announced that seven abstracts from its clinical pipeline were accepted for presentation at the 2026 European Society of Medical Oncology (ESMO) Congress in Madrid. The updates cover several lead programs, including EIK1001, EIK1003, EIK1004, and EIK1005, across a range of cancers. For EIK1001, the company will share Phase 2 results in stage IV non-small cell lung cancer, including data from the squamous cohort, as well as a Phase 2/3 study combining the drug with pembrolizumab and chemotherapy. EIK1003 data will include studies in metastatic prostate cancer and advanced solid tumors. EIK1004 will be presented as a first-in-human study in patients with advanced solid tumors carrying HRR mutations. EIK1005 presentations will cover its use as a monotherapy and with pembrolizumab, along with safety, tolerability, and pharmacokinetic findings. The company said the abstracts reflect progress across its pipeline, but noted that forward-looking statements should not be relied on too heavily.Read Announcement
